Original articles
Huanmin Niu, Lilin Qian, Bin Sun, Wenjian Liu, Fang Wang, Qian Wang, Xiaotian Ji, Yanhai Luo, Effat Un Nesa, Hongxiang Lou, Huiqing Yuan. Inactivation of TFEB and NF-κB by marchantin M alleviates the chemotherapy-driven protumorigenic senescent secretion[J]. Acta Pharmaceutica Sinica B, 2019, 9(5): 923-936

Inactivation of TFEB and NF-κB by marchantin M alleviates the chemotherapy-driven protumorigenic senescent secretion
Huanmin Niua, Lilin Qiana, Bin Sunb, Wenjian Liua, Fang Wanga, Qian Wanga, Xiaotian Jia, Yanhai Luoa, Effat Un Nesac, Hongxiang Loub, Huiqing Yuana
a Institute of Medical Sciences/Department of Biochemistry and Molecular Biology, the Second Hospital of Shandong University, Jinan 250033, China;
b Key Laboratory of Natural Products & Chemical Biology, Ministry of Education, Department of Natural Products Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China;
c Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan 250012, China
It is critical to regulate the senescence-associated secretory phenotype (SASP) due to its effect on promoting malignant phenotypes and limiting the efficiency of cancer therapy. In this study, we demonstrated that marchantin M (Mar-M, a naturally occurring bisbibenzyl) suppressed proinflammatory SASP components which were elevated in chemotherapy-resistant cells. Mar-M treatment attenuated the pro-tumorigenic effects of SASP and enhanced survival in drug-resistant mouse models. No toxicity was detected on normal fibroblast cells or in animals following this treatment. Inactivation of transcription factor EB (TFEB) and nuclear factor-κB (NF-κB) by Mar-M significantly accounted for its suppression on the components of SASP. Furthermore, inhibition of SASP by Mar-M contributed to a synergistic effect during co-treatment with doxorubicin to lower toxicity and enhance antitumor efficacy. Thus, chemotherapy-driven pro-inflammatory activity, seen to contribute to drug-resistance, is an important target for Mar-M. By decreasing SASP, Mar-M may be a potential approach to overcome tumor malignancy.
Key words:    SASP    Marchantin M    TFEB    NF-κB    Drug resistance   
Received: 2019-07-01     Revised: 2019-08-04
DOI: 10.1016/j.apsb.2019.08.007
Funds: This work was supported by the National Natural Science Foundation of China (81473238, 81872896, and 81874293), and the Shandong Key Innovative Research Program (2018CXGC1216, China).
Corresponding author: Huiqing Yuan     Email:lyuanhq@sdu.edu.cn
Author description:
PDF(KB) Free
Huanmin Niu
Lilin Qian
Bin Sun
Wenjian Liu
Fang Wang
Qian Wang
Xiaotian Ji
Yanhai Luo
Effat Un Nesa
Hongxiang Lou
Huiqing Yuan

1. Ewald J, Desotelle J, Almassi N, Jarrard D. Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. Br J Canc 2008;98:1244-9.
2. Sha M, Mao G, Wang G, Chen Y, Wu X, Wang Z. DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis. Acta Pharm Sin B 2015;5:188-93.
3. He S, Sharpless NE. Senescence in health and disease. Cell 2017;169:1000-11.
4. Herranz N, Gil J. Mechanisms and functions of cellular senescence. J Clin Investig 2018;128:1238-46.
5. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype:therapeutic opportunities. J Clin Investig 2013;123:966-72.
6. Velarde MC, Demaria M, Campisi J. Senescent cells and their secretory phenotype as targets for cancer therapy. Interdiscip Top Gerontol 2013;38:17-27.
7. Sagiv A, Krizhanovsky V. Immunosurveillance of senescent cells:the bright side of the senescence program. Biogerontology 2013;14:617-28.
8. Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence. Trends Cell Biol 2018;28:436-53.
9. Ovadya Y, Krizhanovsky V. Strategies targeting cellular senescence. J Clin Investig 2018;128:1247-54.
10. Sun Y, Coppe JP, Lam EW. Cellular senescence:the sought or the unwanted?. Trends Mol Med 2018;24:871-85.
11. Maria J, Ingrid Z. Effects of bioactive compounds on senescence and components of senescence associated secretory phenotypes in vitro. Food Funct 2017;8:2394-418.
12. Malavolta M, Costarelli L, Giacconi R, Piacenza F, Basso A, Pierpaoli E, et al. Modulators of cellular senescence:mechanisms, promises, and challenges from in vitro studies with dietary bioactive compounds. Nutr Res 2014;34:1017-35.
13. Han DW, Lee MH, Kim B, Lee JJ, Hyon SH, Park JC. Preventive effects of epigallocatechin-3-O-gallate against replicative senescence associated with p53 acetylation in human dermal fibroblasts. Oxid Med Cell Longev 2012;2012:850684.
14. Lim H, Park H, Kim HP. Effects of flavonoids on senescenceassociated secretory phenotype formation from bleomycin-induced senescence in BJ fibroblasts. Biochem Pharmacol 2015;96:337-48.
15. Zhang N, Li Z, Xu K, Wang Y, Wang Z. Resveratrol protects against high-fat diet induced renal pathological damage and cell senescence by activating SIRT1. Biol Pharm Bull 2016;39:1448-54.
16. Luo H, Yang A, Schulte BA, Wargovich MJ, Wang GY. Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage. PLoS One 2013;8:e60065.
17. Jiang H, Sun J, Xu Q, Liu Y, Wei J, Young CY, et al. Marchantin M:a novel inhibitor of proteasome induces autophagic cell death in prostate cancer cells. Cell Death Dis 2013;4:e761.
18. Niu L, Deng J, Zhu F, Zhou N, Tian K, Yuan H, et al. Anti-inflammatory effect of marchantin M contributes to sensitization of prostate cancer cells to docetaxel. Cancer Lett 2014;348:126-34.
19. Zhang D, Cui Y, Niu L, Xu X, Tian K, Young CY, et al. Regulation of SOD2 and beta-arrestin 1 by interleukin-6 contributes to the increase of IGF-1R expression in docetaxel resistant prostate cancer cells. Eur J Cell Biol 2014;93:289-98.
20. Malaquin N, Martinez A, Rodier F. Keeping the senescence secretome under control:molecular reins on the senescence-associated secretory phenotype. Exp Gerontol 2016;82:39-49.
21. O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 2011;10:126.
22. Siegert I, Schodel J, Nairz M, Schatz V, Dettmer K, Dick C, et al. Ferritin-mediated iron sequestration stabilizes hypoxia-inducible factor-1 alpha upon LPS activation in the presence of ample oxygen. Cell Rep 2015;13:2048-55.
23. Pastore N, Brady OA, Diab HI, Martina JA, Sun L, Huynh T, et al. TFEB and TFE3 cooperate in the regulation of the innate immune response in activated macrophages. Autophagy 2016;12:1240-58.
24. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007;170:793-804.
25. Zhang B, Lam EW, Sun Y. Senescent cells:a new Achilles' heel to exploit for cancer medicine?. Aging Cell 2019;18:e12875.
26. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
27. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012; 18:1359-68.
28. Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol 2015;17:1049-61.
29. Moiseeva O, Deschenes-Simard X, St-Germain E, Igelmann S, Huot G, Cadar AE, et al. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation. Aging Cell 2013;12:489-98.
30. Crescenzi E, Pacifico F, Lavorgna A, De Palma R, D'Aiuto E, Palumbo G, et al. NF-kappaB-dependent cytokine secretion controls Fas expression on chemotherapy-induced premature senescent tumor cells. Oncogene 2011;30:2707-17.
31. Brady OA, Martina JA, Puertollano R. Emerging roles for TFEB in the immune response and inflammation. Autophagy 2018;14:181-9.